News

Major shareholder announcement

May 9, 2023

Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Nordic Compound Invest A/S that Nordic Compound Invest A/S holds shares, corresponding to more than 5% of the total share capital and voting rights in the Company.

Major shareholder announcement

Read more

Major shareholder announcement

May 9, 2023

Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from MH Investment ApS, that as of May 8, 2023, MH Investment ApS holds shares, corresponding to more than 5% of the total share capital and voting rights in the Company.

Major shareholder announcement

Read more

Notice to convene Annual General Meeting

Apr 25, 2023

Orphazyme A/S (ORPHA.CO) (the “Company”), today announces the notice to convene the Company’s Annual General Meeting to be held on: Wednesday, May 17, 2023 at 11:00 AM (CEST) at the offices of Gorrissen Federspiel, Axeltorv 2, DK-1609 Copenhagen V.

Notice to Convene AGM 2023

Appendix 1 Candidates for the Board of Directors

Announcement Notice to convene AGM 2023

Read more

Orphazyme Announces Publication of 2022 Financial Results and Annual Report

Apr 25, 2023

Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today announced its financial results for the period from January 1, 2022, to December 31, 2022, and publishes its Annual Report.

Announcement Annual Report 2022

Annual Report 2022

Read more

Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States

Apr 17, 2023

Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), announces that publication of its financial results for the full year ending December 31, 2022, previously expected April 19, 2023, are now expected to be published on April 25, 2023. Additional time is required to conclude the presentation of the financial statements. The updated financial calendar for 2023 is available on the Company’s website.

Update of RA release date

Read more

Orphazyme reports financial results in Interim Report First Half 2022

Sep 26, 2022

Orphazyme A/S (ORPHA.CO) (the “Company”) today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2022.

Orphazyme reports financial results in Interim Report First Half 2022

Orphazyme Interim Report H1 2022

Read more

Adjusted financial outlook for 2022

Sep 25, 2022

Orphazyme A/S (ORPHA.CO) (the “Company”) has decided to adjust its outlook for 2022, as published on June 7, 2022.

Adjusted financial outlook for 2022

Read more

Updated financial calendar for 2022

Sep 19, 2022

Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022.

Updated Financial Calendar for 2022 H1 update

Read more

Resolutions passed at the Annual General Meeting

Jun 29, 2022

Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting.

Resolutions passed at the Annual General Meeting

Read more

Updated notice to holders of ADSs regarding termination of Deposit Agreement

Jun 20, 2022

Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) representing deposited common shares of the Company regarding termination of the Deposit Agreement (the “Deposit Agreement”) dated September 28, 2020 among the Company, The Bank of New York Mellon, as depositary (the “the Depositary”), and Owners and ADR Holders (“ADR Holders”).

Updated notice to holders of ADSs regarding termination of Deposit Agreement

Read more

1 2 3 4 5 6 ... 23